Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, reported the regulatory authorization of eftilagimod alpha manufactured at commercial 2,000L scale for use in clinical trials across multiple European countries including Germany, Belgium, Denmark, and the UK.

After successfully scaling up the manufacturing process to commercial scale at WuXi Biologics, the process-related changes were presented in a substantial amendment of the investigational medicinal product dossier (IMPD). Overall comparability of the first 2,000L and the previous 200L scale clinical stage manufacturing process was achieved. Immutep plans to introduce eftilagimod alpha manufactured by the 2,000L scale process into current and future clinical trials.

Marc Voigt, CEO of Immutep, said, “With late-stage clinical development underway for our first-in-class soluble LAG-3 protein and MHC Class II agonist in non-small cell lung cancer, head and neck cancer, and metastatic breast cancer, commercial scale manufacturing of efti for use in clinical trials is a significant achievement and brings us closer to realizing efti’s potential to help cancer patients worldwide”.